Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Allogene Therapeutics, Inc. (ALLO)

Allogene CFO Geoffrey Parker to retire effective November 6, 2026

Neutral Impact 4 of 5 leadership Written later

Allogene Therapeutics disclosed that Chief Financial Officer Geoffrey Parker gave notice on August 31, 2026 that he will retire from the company in all capacities, effective November 6, 2026. The filing does not name a successor or describe the reasons for the departure.

Key points

  • Geoffrey Parker, Executive Vice President and Chief Financial Officer and principal financial officer, provided notice of retirement on August 31, 2026
  • Retirement is effective November 6, 2026
  • The filing does not name a successor or interim financial officer

The filing

CompanyAllogene Therapeutics, Inc. (ALLO)
Form8-K, current report
Filed with the SECSep 2, 2026, 8:35 AM ET
Accession number0001193125-26-379423

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.